Lipoprotein (a) in calcific aortic valve disease:From genomics to novel drug target for aortic stenosis

Journal of Lipid Research

Volumn 57, Issue 6, 2016, Pages 917-924

  Thanassoulis, George ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Calcium; Drug therapy hypolipidemic drugs; Lipoproteins; Mendelian randomization; Oxidized lipids

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TOLL LIKE RECEPTOR 4; ANTILIPEMIC AGENT; CALCIUM;

AORTA STENOSIS; AORTA VALVE DISEASE; BINDING SITE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG TARGETING; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEALTH CARE COST; HEART CYCLE; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LPA GENE; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; SINGLE NUCLEOTIDE POLYMORPHISM; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; LIPID PEROXIDATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; CALCIUM; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID PEROXIDATION; LIPOPROTEIN(A); MOLECULAR TARGETED THERAPY;

EID: 84971569675     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R051870     Document Type: Review

References (62)

1. Bach, D. S., J. I. Radeva, H. G. Birnbaum, A. A. Fournier, and E. G. Tuttle. 2007. Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind? J. Heart Valve Dis. 16: 362-369.
2. Mozaffarian, D., E. J. Benjamin, A. S. Go, D. K. Arnett, M. J. Blaha, M. Cushman, S. de Ferranti, J. P. Despres, H. J. Fullerton, V. J. Howard, et al. 2015. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 131: 434-441.
3. Yutzey, K. E., L. L. Demer, S. C. Body, G. S. Huggins, D. A. Towler, C. M. Giachelli, M. A. Hofmann-Bowman, D. P. Mortlock, M. B. Rogers, M. M. Sadeghi, et al. 2014. Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. Arterioscler. Thromb. Vasc. Biol. 34: 2387-2393.
4. Osnabrugge, R. L., D. Mylotte, S. J. Head, N. M. Van Mieghem, V. T. Nkomo, C. M. LeReun, A. J. Bogers, N. Piazza, and A. P. Kappetein. 2013. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J. Am. Coll. Cardiol. 62: 1002-1012.
5. Go, A. S., D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, M. J. Blaha, S. Dai, E. S. Ford, C. S. Fox, S. Franco, et al. 2014. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 129: e28-e292.
6. Lindroos, M., M. Kupari, J. Heikkila, and R. Tilvis. 1993. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J. Am. Coll. Cardiol. 21: 1220-1225.
7. Otto, C. M., B. K. Lind, D. W. Kitzman, B. J. Gersh, and D. S. Siscovick. 1999. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N. Engl. J. Med. 341: 142-147.
8. O'Brien, K. D., D. D. Reichenbach, S. M. Marcovina, J. Kuusisto, C. E. Alpers, and C. M. Otto. 1996. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler. Thromb. Vasc. Biol. 16: 523-532.
9. Otto, C. M., J. Kuusisto, D. D. Reichenbach, A. M. Gown, and K. D. O'Brien. 1994. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 90: 844-853.
10. Stewart, B. F., D. Siscovick, B. K. Lind, J. M. Gardin, J. S. Gottdiener, V. E. Smith, D. W. Kitzman, and C. M. Otto. 1997. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J. Am. Coll. Cardiol. 29: 630-634.
11. Thanassoulis, G., J. M. Massaro, R. Cury, E. Manders, E. J. Benjamin, R. S. Vasan, L. A. Cupple, U. Hoffmann, C. J. O'Donnell, and S. Kathiresan. 2010. Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium. J. Am. Coll. Cardiol. 55: 2491-2498.
12. Demer, L., and Y. Tintut. 2011. The roles of lipid oxidation products and receptor activator of nuclear factor-kappaB signaling in atherosclerotic calcification. Circ. Res. 108: 1482-1493.
13. Kvidal, P., R. Bergstrom, L-G. Horte, and E. Stahle. 2000. Observed and relative survival after aortic valve replacement. J. Am. Coll. Cardiol. 35: 747-756.
14. Chan, K. L., K. Teo, J. G. Dumesnil, A. Ni, and J. Tam; ASTRONOMER Investigators. 2010. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 121: 306-314.
15. Cowell, S. J., D. E. Newby, R. J. Prescott, P. Bloomfield, J. Reid, D. B. Northridge, and N. A. Boon; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. 2005. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 352: 2389-2397.
16. Rossebø, A. B., T. R. Pedersen, K. Boman, P. Brudi, J. B. Chambers, K. Egstrup, E. Gerdts, C. Gohlke-Bärwolf, I. Holme, Y. A. Kesaniemi, et al. 2008. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359: 1343-1356.
17. Deleted in proof
18. Gotoh, T., T. Kuroda, M. Yamasawa, M. Nishinaga, T. Mitsuhashi, Y. Seino, N. Nagoh, K. Kayaba, S. Yamada, H. Matsuo, et al. 1995. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am. J. Cardiol. 76: 928-932.
19. Bozbas, H., A. Yildirir, I. Atar, B. Pirat, S. Eroglu, A. Aydinalp, B. Ozin, and H. Muderrisoglu. 2007. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J. Heart Valve Dis. 16: 387-393.
20. Glader, C. A., L. S. Birgander, S. Soderberg, H. P. Ildgruben, P. Saikku, A. Waldenstrom, and G. H. Dahlen. 2003. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur. Heart J. 24: 198-208.
21. Thanassoulis, G., C. Y. Campbell, D. S. Owens, J. G. Smith, A. V. Smith, G. M. Peloso, K. F. Kerr, S. Pechlivanis, M. J. Budoff, T. B. Harris, et al. 2013. Genetic associations with valvular calcification and aortic stenosis. N. Engl. J. Med. 368: 503-512.
22. Tracy, R. P. 2008. 'Deep phenotyping': characterizing populations in the era of genomics and systems biology. Curr. Opin. Lipidol. 19: 151-157.
23. Clarke, R., J. F. Peden, J. C. Hopewell, T. Kyriakou, A. Goel, S. C. Heath, S. Parish, S. Barlera, M. G. Franzosi, S. Rust, et al. 2009. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361: 2518-2528.
24. Thanassoulis, G. 2013. Mendelian randomization: how genetics is pushing the boundaries of epidemiology to identify new causes of heart disease. Can. J. Cardiol. 29: 30-36.
25. Thanassoulis, G., and C. J. O'Donnell. 2009. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA. 301: 2386-2388.
26. Kamstrup, P. R., A. Tybjaerg-Hansen, and B. G. Nordestgaard. 2014. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J. Am. Coll. Cardiol. 63: 470-477.
27. Arsenault, B. J., S. M. Boekholdt, M. P. Dube, E. Rheaume, N. J. Wareham, K. T. Khaw, M. S. Sandhu, and J. C. Tardif. 2014.Lipoprotein(a) levels, genotype and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 7: 304-310.
28. Capoulade, R., K. L. Chan, C. Yeang, P. Mathieu, Y. Bosse, J. G. Dumesnil, J. W. Tam, K. K. Teo, A. Mahmut, X. Yang, et al. 2015. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J. Am. Coll. Cardiol. 66: 1236-1246.
29. Nielsen, L. B., S. Stender, K. Kjeldsen, and B. G. Nordestgaard. 1996. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ. Res. 78: 615-626.
30. Miller, Y. I., S-H. Choi, P. Wiesner, L. Fang, R. Harkewicz, K. Hartvigsen, A. Boullier, A. Gonen, C. J. Diehl, X. Que, et al. 2011. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108: 235-248.
31. Seimon, T. A., M. J. Nadolski, X. Liao, J. Magallon, M. Nguyen, N. T. Feric, M. L. Koschinsky, R. Harkewicz, J. L. Witztum, S. Tsimikas, et al. 2010. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12: 467-482.
32. Wiesner, P., M. Tafelmeier, D. Chittka, S. H. Choi, L. Zhang, Y. S. Byun, F. Almazan, X. Yang, N. Iqbal, P. Chowdhury, et al. 2013. MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J. Lipid Res. 54: 1877-1883.
33. Ketelhuth, D. F., F. J. Rios, Y. Wang, H. Liu, M. E. Johansson, G. N. Fredrikson, U. Hedin, M. Gidlund, J. Nilsson, G. K. Hansson, et al. 2011. Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate proatherogenic responses. Circulation. 124: 2433-2443.
34. Tsimikas, S., E. S. Brilakis, E. R. Miller, J. P. McConnell, R. J. Lennon, K. S. Kornman, J. L. Witztum, and P. B. Berger. 2005. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353: 46-57.
35. Bergmark, C., A. Dewan, A. Orsoni, E. Merki, E. R. Miller, M. J. Shin, C. J. Binder, S. Horkko, R. M. Krauss, M. J. Chapman, et al. 2008. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49: 2230-2239.
36. Tsimikas, S., P. Clopton, E. S. Brilakis, S. M. Marcovina, A. Khera, E. R. Miller, J. A. de Lemos, and J. L. Witztum. 2009. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation. 119: 1711-1719.
37. Tsimikas, S., S. Kiechl, J. Willeit, M. Mayr, E. R. Miller, F. Kronenberg, Q. Xu, C. Bergmark, S. Weger, F. Oberhollenzer, et al. 2006. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J. Am. Coll. Cardiol. 47: 2219-2228.
38. Deleted in proof
39. Matzinger, P. 2002. The danger model: a renewed sense of self. Science. 296: 301-305.
40. Deleted in proofDeleted in proof.
41. Leitinger, N., T. R. Tyner, L. Oslund, C. Rizza, G. Subbanagounder, H. Lee, P. T. Shih, N. Mackman, G. Tigyi, M. C. Territo, et al. 1999. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc. Natl. Acad. Sci. USA. 96: 12010-12015.
42. Subbanagounder, G., N. Leitinger, D. C. Schwenke, J. W. Wong, H. Lee, C. Rizza, A. D. Watson, K. F. Faull, A. M. Fogelman, and J. A. Berliner. 2000. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler. Thromb. Vasc. Biol. 20: 2248-2254.
43. Bae, Y. S., J. H. Lee, S. H. Choi, S. Kim, F. Almazan, J. L. Witztum, and Y. I. Miller. 2009. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: tolllike receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ. Res. 104: 210-218.
44. Hirsch, D., R. Azoury, S. Sarig, and H. S. Kruth. 1993. Colocalization of cholesterol and hydroxyapatite in human atherosclerotic lesions. Calcif. Tissue Int. 52: 94-98.
45. Mody, N., F. Parhami, T. A. Sarafian, and L. L. Demer. 2001. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic. Biol. Med. 31: 509-519.
46. Liberman, M., E. Bassi, M. K. Martinatti, F. C. Lario, J. Wosniak, Jr., P. M. Pomerantzeff, and F. R. Laurindo. 2008. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler. Thromb. Vasc. Biol. 28: 463-470.
47. Ducy, P., R. Zhang, V. Geoffroy, A. L. Ridall, and G. Karsenty. 1997. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 89: 747-754.
48. Parhami, F., A. D. Morrow, J. Balucan, N. Leitinger, A. D. Watson, Y. Tintut, J. A. Berliner, and L. L. Demer. 1997. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation: a possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 17: 680-687.
49. Mahmut, A., M. C. Boulanger, D. El Husseini, D. Fournier, R. Bouchareb, J. P. Despres, P. Pibarot, Y. Bosse, and P. Mathieu. 2014. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J. Am. Coll. Cardiol. 63: 460-469.
50. Kadl, A., P. R. Sharma, W. Chen, R. Agrawal, A. K. Meher, S. Rudraiah, N. Grubbs, R. Sharma, and N. Leitinger. 2011. Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2. Free Radic. Biol. Med. 51: 1903-1909.
51. Yang, X., D. A. Fullerton, X. Su, L. Ao, J. C. Cleveland, Jr., and X. Meng. 2009. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J. Am. Coll. Cardiol. 53: 491-500.
52. Bouchareb, R., A. Mahmut, M. J. Nsaibia, M. C. Boulanger, A. Dahou, J. L. Lepine, M. H. Laflamme, F. Hadji, C. Couture, S. Trahan, et al. 2015. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation. 132: 677-690.
53. Teo, K. K., D. J. Corsi, J. W. Tam, J. G. Dumesnil, and K. L. Chan. 2011. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients. Can. J. Cardiol. 27: 800-808.
54. Mundy, G., R. Garrett, S. Harris, J. Chan, D. Chen, G. Rossini, B. Boyce, M. Zhao, and G. Gutierrez. 1999. Stimulation of bone formation in vitro and in rodents by statins. Science. 286: 1946-1949.
55. Smith, J. G., K. Luk, C. A. Schulz, J. C. Engert, R. Do, G. Hindy, G. Rukh, L. Dufresne, P. Almgren, D. S. Owens, et al. 2014. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA. 312: 1764-1771.
56. Merki, E., M. Graham, A. Taleb, G. Leibundgut, X. Yang, E. R. Miller, W. Fu, A. E. Mullick, R. Lee, P. Willeit, et al. 2011. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol. 57: 1611-1621.
57. Raal, F. J., R. P. Giugliano, M. S. Sabatine, M. J. Koren, G. Langslet, H. Bays, D. Blom, M. Eriksson, R. Dent, S. M. Wasserman, et al. 2014. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J. Am. Coll. Cardiol. 63: 1278-1288.
58. Graham, M. J., N. Viney, R. Crooke, and S. Tsimikas. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J. Lipid Res. Epub ahead of print. November 4, 2015; doi:10.1194/jlr.R052258.
59. Thanassoulis, G. 2015. Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL). Accessed December 11, 2015, at https://clinicaltrials.gov/ct2/show/NCT02109614.
60. Tsimikas, S., N. J. Viney, S. G. Hughes, W. Singleton, M. J. Graham, B. F. Baker, J. L. Burkey, Q. Yang, S. M. Marcovina, R. S. Geary, et al. 2015. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 386: 1472-1483.
61. Dweck, M. R., W. S. Jenkins, A. T. Vesey, M. A. Pringle, C. W. Chin, T. S. Malley, W. J. Cowie, V. Tsampasian, H. Richardson, A. Fletcher, et al. 2014. 18F-sodium fluoride uptake is a marker of active calcification and disease progression in patients with aortic stenosis. Circ Cardiovasc Imaging. 7: 371-378.
62. Dweck, M. R., C. Jones, N. V. Joshi, A. M. Fletcher, H. Richardson, A. White, M. Marsden, R. Pessotto, J. C. Clark, W. A. Wallace, et al. 2012. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 125: 76-86.